Weiss Ratings Reiterates “Sell (D-)” Rating for 2seventy bio (NASDAQ:TSVT)

2seventy bio (NASDAQ:TSVT)‘s stock had its “sell (d-)” rating reissued by Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

2seventy bio Stock Up 7.5 %

TSVT opened at $2.57 on Wednesday. The company has a market cap of $132.59 million, a price-to-earnings ratio of -1.38 and a beta of 1.74. 2seventy bio has a 52-week low of $2.29 and a 52-week high of $6.40. The firm’s fifty day simple moving average is $2.72 and its two-hundred day simple moving average is $3.85.

Hedge Funds Weigh In On 2seventy bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TSVT. SG Americas Securities LLC purchased a new position in 2seventy bio during the third quarter valued at $80,000. GSA Capital Partners LLP acquired a new stake in shares of 2seventy bio in the third quarter valued at about $64,000. Intech Investment Management LLC acquired a new stake in shares of 2seventy bio in the third quarter valued at about $69,000. FMR LLC raised its position in shares of 2seventy bio by 22.0% in the third quarter. FMR LLC now owns 148,545 shares of the company’s stock valued at $701,000 after buying an additional 26,738 shares during the last quarter. Finally, BBR Partners LLC raised its position in shares of 2seventy bio by 620.0% in the third quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after buying an additional 155,000 shares during the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.